Furthermore, PD-L1 expression and CD8+ T cell infiltration might act as biomarkers to predict the efficacy of PD-1/PD-L1 inhibitors in patients with NSCLC and liver metastasis. Here, CD8A is linked to non-small cell lung carcinoma.